Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model
October 14, 2020 07:00 ET
|
Novan, Inc.
- First demonstration of antiviral effect of nitric oxide-based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium - Company believes preclinical results...
Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors
September 24, 2020 07:05 ET
|
Novan, Inc.
- John M. Gay, Vice President, Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer - James L. Bierman, seasoned industry...
Novan Provides Pipeline and Priority Development Programs Update
September 14, 2020 09:05 ET
|
Novan, Inc.
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 - - In vitro assessments of ability of...
Novan to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 08:05 ET
|
Novan, Inc.
- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14th at 4:00 PM EDT - MORRISVILLE, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or...
Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
September 03, 2020 09:05 ET
|
Novan, Inc.
- Topline results targeted for Q2 2021, less than a year away - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved...
Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
August 31, 2020 08:05 ET
|
Novan, Inc.
- Clinical sites actively enrolling patients - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment - ...
Novan President and CEO, Paula Brown Stafford Named Chairman of the Board
July 28, 2020 08:05 ET
|
Novan, Inc.
Expanded role of Ms. Stafford as Chairman reflects the Board’s confidence in her leadership of the Company and strategic direction Renowned pharmaceutical executive Robert Ingram retiring as Executive...
Novan to Host Live Audio Webcast of 2020 Annual Meeting of Stockholders
July 23, 2020 08:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2020 Annual...
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
June 25, 2020 08:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., June 25, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be...
Novan to Present at Virtual Life Sciences Investor Forum on June 25
June 24, 2020 08:15 ET
|
Novan, Inc.
MORRISVILLE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executive...